Trial Comparing Pirtobrutinib With Bendamustine Plus Rituximab in CLL/SLL
The study’s primary outcome is progression-free survival by independent review.
All articles by Cancer Therapy Advisor Staff
Tafasitamab Plus Lenalidomide and Rituximab for Follicular Lymphoma and Marginal Zone Lymphoma
The primary outcome measure is progression-free survival.
Trial to Compare Diets in Patients With Leukemia or MDS and Prolonged Neutropenia
The trial’s primary objective is to compare the incidence of major infections.
Phase 3 Trial Comparing Rituximab Biosimilar and Originator in Follicular Lymphoma
The primary outcome measure is overall response rate.
Phase 3 Trial Evaluating the Combination of Ibrutinib and Rituximab for Marginal Zone Lymphoma
The trial is designed to compare rituximab plus ibrutinib with rituximab plus placebo.
Trial to Test Risk Factors, Pegaspargase Dosing in Children, Adolescents With Acute Lymphoblastic Leukemia
Researchers are testing a new set of risk factors and pharmacokinetic-adjusted dosing in pediatric ALL.
Acalabrutinib for Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia
Researchers are evaluating the safety and efficacy of acalabrutinib in 3 cohorts.
Trial to Evaluate Polatuzumab Vedotin Plus R-GemOx in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Researchers will compare polatuzumab vedotin plus R-GemOx with R-GemOx alone.
Transcranial Direct Current Stimulation in Adult Survivors of Pediatric Acute Lymphoblastic Leukemia
The primary outcome of the study is to evaluate the efficacy of home-based tDCS combined with remote cognitive training on direct testing of executive function in survivors of ALL.
SYMPATICO Trial: Ibrutinib Plus Venetoclax in Patients With Mantle Cell Lymphoma
Researchers are seeking to compare the efficacy and safety of the combination of ibrutinib and venetoclax compared with ibrutinib and placebo in patients with mantle cell lymphoma.
- Loading...
Loading...
Next post in Hematologic Cancers
Loading... 
Loading...